Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy <sup>*</sup>

Miyamoto, Toshihiro; Sanford, David; Tomuleasa, Ciprian; Hsiao, Hui‐Hua; José Enciso Olivera, Leonardo; Enjeti, Anoop; Giménez Conca, Alberto; Bernal, Teresa; Girshova, Larisa; Paola Martelli, Maria; Güvenç, Birol; Delgado, Alexander; Duan, Yinghui; Garbayo Guijarro, Belen; Llamas, Cynthia; Lee, Je‐Hwan

doi:10.1080/10428194.2021.2002321

Public

Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy *

Published in Leukemia & lymphoma/Leukemia and lymphoma • Feb 11, 2022

Authors:

Toshihiro Miyamoto

David Sanford

Ciprian Tomuleasa

Abstract

Acute myeloid leukemia (AML) predominantly affects the elderly, and prognosis declines with age. Induction chemotherapy plus consolidation therapy is standard of care for fit patients; options for unfit patients include hypomethylating agents (HMA), low-dose cytarabine (LDAC), targeted therapies, an...

Subject

Medicine

Cytarabine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!